“…Cancer-associated SVs can disrupt the physiological 3D genome structure by causing A/B compartments switching (Dubois et al, 2022)or TAD reorganization (shuffling, fusion or neo-formation) (Lupiáñez et al, 2015;San Martin et al, 2021;Xu Z. et al, 2022), resulting in the ectopic activation of oncogenes or inhibition of tumor-suppressing genes (Liu et al, 2023). That is the case for several primary and metastatic prostate cancer cell lines, where SVsmediated DNA loci transition from the inactive to active compartment and vice versa can cause the fusion of TMPRSS2-ERG genesa marker used for prostate cancer malignancy stratification - (San Martin et al, 2021), and the activation of numerous genes linked to carcinogenesis (i.e., WNT5, TMPRS, and CDK44) (San Martin et al, 2021) (Table 1).…”